Experimental pill breakthrough sees cancer vanish in a third of leukaemia patients
WORLD 26 March 2023 - 00:03
Terminal leukaemia patients who were not responding to treatment now have hope for a cure, thanks to a new experimental pill called revumenib.
This drug has completely eliminated cancer in a third of the participants in a long-awaited clinical trial in the United States.
Although not all patients showed complete remission, scientists remain hopeful as the results indicate that the pill might pave the way to a cure for leukaemia in the future.
"We're incredibly hopeful by these results of patients that received this drug. This was their last chance," said study co-author Dr Ghayas Issa, a leukaemia physician at the MD Anderson Cancer Center at the University of Texas.
"They have progressed on multiple lines of therapy and a fraction of them, about half, had disappearance of their leukaemia cells from their bone marrow," he told Euronews Next.
How does this pill work?
Acute myeloid leukaemia (AML) is a type of cancer that attacks the bone marrow, where blood cells are produced, and causes the uncontrolled production of defective cells.
Revumenib is a new class of targeted therapy for acute leukaemia that inhibits a specific protein called menin. The drug works by reprogramming leukaemia cells back into normal cells.
Menin is involved in the complex machinery that gets hijacked by leukaemia cells and causes normal blood cells to turn into cancerous ones.
By using revumenib, Issa explained, the engine is turned off and leukaemia cells are turned back into normal cells, resulting in remission.
This formula has already saved 18 lives as part of the clinical trial, whose promising results were published this month in Nature.
The preliminary results showed that 53 per cent of patients responded to revumenib, and 30 per cent had a complete remission with no cancer detectable in their blood.
Based on the data from this trial, in December 2022 the US Food and Drug Administration granted revumenib "breakthrough therapy designation" to help fast-track its development and regulatory review.
A leukaemia cure, but not for everyone
"This is definitely a breakthrough and it's a result of years of science. A lot of groups had worked hard in the lab to understand what is causing these leukaemias," Issa said.
However, he explained that the drug does not work for all patients. It is for a specific subset of leukaemias that generally have missing or mislabeled genes or a chromosome fusion.
The experimental pill targets the most common mutation in acute myeloid leukaemia, a gene called NPM1, and a less common fusion called KMT2A. Combined, these mutations are estimated to occur in about 30 to 40 per cent of people with acute myeloid leukaemia.
The phase 1 trial enrolled 68 patients at nine US hospitals. All of them had seen their leukaemia return after other treatments or had never responded well to traditional chemotherapy drugs in the first place.
Among them was Algimante Daugeliate, a 23-year-old Lithuanian architect diagnosed with leukaemia. She had received two bone marrow transplants from her sister, but all other treatments had failed. Her doctors had even considered palliative care to ease her suffering.
"I was desperate. It was like living through a horrible movie. I felt like death was imminent, and I was just 21 years old," she told El Pais.
However, once she started taking revumenib two years ago, Daugeliate made a full recovery. Since then, she has been able to resume her normal life, graduating from college and working at an architecture studio in Copenhagen.
Strong impact for limited side effects
According to Issa, although this drug is fairly safe when compared to standard treatments for leukaemia, two main side effects have been identified.
The first affects the heart’s electrical system and can be detected with an electrocardiogram (ECG). However, reducing the dosage or halting the treatment resolved the issue in all cases, Issa said.
The second side effect is referred to as differentiation syndrome - a group of potentially life-threatening reactions to blood cancer treatments - but it can be managed effectively if it’s recognised early and appropriate measures are taken to shut it down. According to Issa, all cases of differentiation syndrome in this study were successfully managed without any complications for the patients.
The study is still in its early stages and the results remain preliminary. Phase I studies like this one aim to test whether a drug is safe and to find the highest dose that can be given to them without causing severe side effects.
A phase II study specifically looking at the effectiveness of revumenib is now underway.
Twelve patients in the trial who responded to the drug went on to receive a stem cell or bone marrow transplant. Such transplants require that patients have no cancer or only very low levels of cancer in their blood - and revumenib helped them get there.
While the experimental pill is not a definitive cure, the researchers who worked on the trial are optimistic.
"In the future, we plan to combine this pill with standard treatments that we have currently for acute leukaemias," said Issa.
"That is the most likely strategy to get us to cures where patients don't have to see leukaemia doctors after that and don't need treatments for leukaemia".
Caliber.Az
1
|
Iran re-evaluating its ties with Azerbaijan, Armenia Baku - more important, honest partner than Yerevan
25 April 2024 - 12:00
|
2
|
"Peoples of South Caucasus should resolve their differences independently" Foreign analysts on Caliber.Az
24 April 2024 - 17:40
|
3
|
Mark Rutte seeks Türkiye's backing for new job A new pair of hands
24 April 2024 - 16:55
|
4
|
Bilateral relations, regional dynamics, & peacekeepers’ withdrawal Key takeaways from President Aliyev's Moscow visit
24 April 2024 - 14:07
|
5
|
Air France plane safely evacuated at Heydar Aliyev Int’l Airport
24 April 2024 - 19:08
|
Türkiye - latest country to launch digital nomad visa
27 April 2024 - 05:04
US National Security Advisor: Defence industry “still underestimating” global need for munitions
27 April 2024 - 03:05
China passes tariff law as tensions with trading partners simmer
27 April 2024 - 01:03
Azerbaijani, German presidents hold expanded meeting
26 April 2024 - 23:50
Azerbaijani President, German Chancellor hold joint press conference
26 April 2024 - 23:45
Mount Fuji view to be blocked as tourists overcrowd popular photo spot
26 April 2024 - 23:00
Türkiye bases its relations with African countries on win-win principle: Parliament speaker
26 April 2024 - 20:53
ICJ concludes public hearings on 'Azerbaijan v. Armenia' case, proceeds to evidence verification
26 April 2024 - 20:45
Turkic parliament committee chairmen tour Khankendi & Shusha in Azerbaijan
26 April 2024 - 20:39
ByteDance prefers TikTok shutdown in US over sale
26 April 2024 - 20:39
Health Ministry: Over 50 Palestinians killed in Gaza as Israeli onslaught continues
26 April 2024 - 20:26
Azerbaijani president meets German FM in Berlin, discusses COP29 & peace agenda
26 April 2024 - 20:22
Russia, Ukraine hand over bodies of dead soldiers
26 April 2024 - 20:11
Political analyst: Armenian leadership hostile towards Russia
26 April 2024 - 19:56
Israeli civilian fatally injured in anti-tank missile strike near Lebanon border
VIDEO26 April 2024 - 19:41
Turkish court sentences Syrian woman to life in prison for bombing in Istanbul in 2022
26 April 2024 - 19:26
Azerbaijani, Kazakh military specialists convene for bilateral co-op discussions
26 April 2024 - 19:16
Armenia, Italy agree on military-technical cooperation
26 April 2024 - 19:11
Kazakhstan hosting meeting of defence ministers of SCO member states
26 April 2024 - 18:56
Azerbaijan, Armenia install 28 markers as border clarification works reach 35% completion
26 April 2024 - 18:50
UK’s ministry: Russian forces accelerating advance west of Ukraine’s Avdiivka
26 April 2024 - 18:41
Kazakh military delegation explores Azerbaijan's defense capabilities during visit
26 April 2024 - 18:35
France, Germany push on with 2040 joint tank project
26 April 2024 - 18:26
Political analyst: Demarcation of border with Azerbaijan meets Armenia’s vital interests
26 April 2024 - 18:11
Palestinian Resistance factions fighting against Israeli forces across besieged Gaza Strip
26 April 2024 - 17:56
US Central Command conducts humanitarian airdrops into Gaza
26 April 2024 - 17:41
Azerbaijan unveils programme of sixth World Forum on Intercultural Dialogue in Baku
26 April 2024 - 17:26
Azerbaijan's energy offer signals path to normalization with Armenia
Amid geopolitical shifts26 April 2024 - 17:24
Spain to send Patriot missiles to Ukraine
26 April 2024 - 17:11
Russia's oil revenues grow despite Western sanctions
Bill of the war26 April 2024 - 17:05
US, China spar over bilateral, global issues
26 April 2024 - 16:56
Kyrgyzstan's school-building gesture in Karabakh signals deeper ties with Azerbaijan
26 April 2024 - 16:41
Armenian PM vows to tackle existential challenges
We will address this issue26 April 2024 - 16:30
Azerbaijani police find explosive devices, ammunition in Khojavend
PHOTO26 April 2024 - 16:28
IAEA: Situation at Zaporizhzhia Nuclear Power Plant remains unpredictable
26 April 2024 - 16:13
US Mojave proves its unmatched versatility in unprecedented live-fire demo
26 April 2024 - 15:58
From energy cooperation to investment expansion
Baku, Budapest forge stronger business ties26 April 2024 - 15:45
Russian operation to seize Chasiv Yar offers most immediate prospects for significant advances
ISW analysts’ opinion26 April 2024 - 15:43
Turkish president to meet with US counterpart at White House in May
26 April 2024 - 15:28
Sweden to move ahead with sending troops to Latvia as part of NATO forces
26 April 2024 - 15:13